Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $63.2352W HIGH $130.00
Volume
591.32 K
Value Traded
85.36 M
Short % Float
12.39%
Days to Cover
7.3
+7.46%Week
+1.06%1 Month
-18.46%3 Month
-10.5%6 Month
+458.44%5 Year
+658.62%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.61 B
EPS (TTM)
-13.25
P/E Ratio
-
Ent. Value
5.80 B
Total Shares
64.93 M
Float Shares
53.79 M
Insiders
17.16%
Institutions
94.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MIRM Catalyst Timeline
Dated clinical, regulatory and corporate events for Mirum Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mirum Pharmaceuticals, Inc.
327Total events
18Upcoming
130Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutzilurgisertibApprovedClinical Data
Positive topline results from PROGRESS Cohort 2 in pediatric patients aged 6 to <12 years
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
▲Primary Endpoint MetzilurgisertibApprovedClinical Data
PROGRESS Cohort 2 met key endpoints at Week 24 (HO lesion volume, joint mobility)
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
▲Safety Data UpdatezilurgisertibApprovedClinical Data
No new safety signals in PROGRESS Cohort 2; no growth plate closure
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
▲Secondary Endpoint DataMaralixibatApprovedClinical Data
Statistically significant pruritus reduction in biliary atresia patients (p=0.0002)
biliary atresia with native liversource ↗
▲Subgroup AnalysisMaralixibatApprovedClinical Data
Statistically significant pruritus reduction in biliary atresia subgroup (p=0.0002)
biliary atresia with native liversource ↗
◆Topline ReadoutLIVMARLIApprovedClinical Data
Topline results from Phase 3 EXPAND study of LIVMARLI (maralixibat) to be shared on investor call
cholestatic pruritus in ultra-rare cholestatic liver diseases, including biliary atresiasource ↗
●Safety Data UpdateMaralixibatApprovedClinical Data
Safety findings consistent with prior experience; no new safety signals
cholestatic pruritus in ultra-rare cholestatic liver diseasessource ↗
▲Primary Endpoint MetMaralixibatApprovedClinical Data
Phase 3 EXPAND met primary endpoint of pruritus reduction in pediatric patients
cholestatic pruritus in ultra-rare cholestatic liver diseasessource ↗
▲Topline ReadoutMaralixibatApprovedClinical Data
Mirum announced topline results from Phase 3 EXPAND study of LIVMARLI (maralixibat)
cholestatic pruritus in ultra-rare cholestatic liver diseases, including biliary atresiasource ↗
◆Topline ReadoutBrelovitugClinical Data
Topline results from Phase 3 AZURE-1 study of Brelovitug in chronic HDV to be shared on investor call
Chronic Hepatitis Deltasource ↗
▲Long Term DataBrelovitugClinical Data
48-week Phase 2b AZURE-1 data show deepening viral suppression and increased ALT normalization
chronic hepatitis delta virus (HDV)source ↗
◆Topline ReadoutBrelovitugClinical Data
Topline results from Phase 3 AZURE-1 study of brelovitug in chronic HDV to be shared on investor call
chronic hepatitis delta virus (HDV)source ↗
▲Primary Endpoint MetBrelovitugClinical Data
Phase 3 AZURE-1 primary endpoint met at Week 24 in chronic HDV
chronic hepatitis delta virus (HDV)source ↗
◆Additional DataBrelovitugClinical Data
48-week data from Phase 2b portion of AZURE-1 study of brelovitug to be shared
chronic hepatitis delta virus (HDV)source ↗
●R&D DayPresentation
Mirum conference call to discuss AZURE-1 topline results
chronic hepatitis delta virus (HDV)source ↗
▲Safety Data UpdateBrelovitugClinical Data
Favorable safety and tolerability profile through Week 24 in Phase 3 AZURE-1; no new safety signals
chronic hepatitis delta virus (HDV)source ↗
◆Full ResultsBrelovitugClinical Data
48-week data from Phase 2b portion of AZURE-1 study of brelovitug to be shared
chronic hepatitis delta virus (HDV)source ↗
▲FDA ApprovalATEBRIOZApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for FOP in adults and pediatric patients ≥12 years
fibrodisplasia ossificante progressiva (FOP)source ↗
▲FDA ApprovalzilurgisertibApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for FOP in adults and pediatric patients 12 years and older
fibrodysplasia ossificans progressiva (FOP)source ↗
▲FDA ApprovalzilurgisertibApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for adult and pediatric patients with Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressivasource ↗
▲FDA ApprovalATEBRIOZApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for FOP in patients aged 12 years and older
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
▲PRV GrantedATEBRIOZApprovedDesignation
FDA issued Rare Pediatric Disease Priority Review Voucher to Incyte
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
▲FDA ApprovalATEBRIOZApprovedFDA Decision
FDA approved ATEBRIOZ for FOP in patients aged 12 years and older
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
◆Topline ReadoutBrelovitugClinical Data
Topline results from AZURE-1 Phase 3 study of brelovitug in chronic HDV expected Q3 2026
chronic hepatitis delta virus (HDV)source ↗
▲Topline ReadoutzilurgisertibApprovedClinical Data
Positive pivotal Phase 2 results from PROGRESS study of Zilurgisertib in FOP
Fibrodysplasia Ossificans Progressivasource ↗
▲Oral PresentationVolixibatPresentation
Late-breaking VISTAS results presented at EASL 2026
primary sclerosing cholangitis (PSC)source ↗
▲Oral PresentationBrelovitugPresentation
Late-breaking Phase 2b AZURE-1 results presented at EASL 2026
chronic hepatitis delta virus (HDV)source ↗
▲Oral PresentationLIVMARLIApprovedPresentation
LIVMARLI data on event-free survival in PFIC presented at EASL 2026
progressive familial intrahepatic cholestasis (PFIC)source ↗
◆Oral PresentationVolixibatPresentation
Volixibat VISTAS full results late-breaking oral presentation at EASL
primary sclerosing cholangitis (PSC)source ↗
◆Poster PresentationBrelovitugPresentation
Brelovitug AZURE-1 full results late-breaking poster at EASL
chronic hepatitis delta virus (HDV)source ↗
▲Primary Endpoint MetVolixibatClinical Data
Volixibat VISTAS Phase 2b met primary endpoint
primary sclerosing cholangitis (PSC)source ↗
▲Primary Endpoint MetBrelovitugClinical Data
Brelovitug Phase 2b portion of AZURE-1 met primary endpoint
chronic hepatitis delta virus (HDV)source ↗
▲Enrollment CompleteBrelovitugTrial
Enrollment completed in brelovitug AZURE-1 and AZURE-4 Phase 3 studies
chronic hepatitis delta virus (HDV)source ↗
▲Enrollment CompleteLIVMARLIApprovedTrial
Enrollment completed in LIVMARLI EXPAND Phase 3 study
additional rare cholestatic conditionssource ↗
▲Partnership / LicensezilurgisertibApprovedCorporate
In-licensed exclusive worldwide rights to zilurgisertib from Incyte
fibrodysplasia ossificans progressiva (FOP)source ↗
▲FDA Filing AcceptedzilurgisertibApprovedRegulatory Filing
FDA accepted NDA for zilurgisertib with Priority Review
fibrodysplasia ossificans progressiva (FOP)source ↗
▲Priority ReviewzilurgisertibApprovedRegulatory Filing
FDA granted Priority Review for zilurgisertib NDA
fibrodysplasia ossificans progressiva (FOP)source ↗
◆Topline ReadoutVolixibatClinical Data
Topline results from VISTAS study of volixibat in PSC
primary sclerosing cholangitissource ↗
◆Topline ReadoutVolixibatClinical Data
Volixibat VISTAS study in PSC topline data expected Q2 2026
primary sclerosing cholangitis (PSC)source ↗
◆Interim AnalysisBrelovitugTrial
Interim data from AZURE-1 expected in Q2 2026
chronic hepatitis delta virussource ↗
◆Topline ReadoutBrelovitugClinical Data
Topline data from AZURE Phase 3 program expected
chronic hepatitis delta virus (HDV)source ↗
◆Pre NDA MeetingVolixibatFDA Meeting
Pre-NDA meeting with FDA for volixibat in PSC scheduled for summer 2026
primary sclerosing cholangitis (PSC)source ↗
▲Enrollment CompleteBrelovitugTrial
AZURE-1 enrollment completed
chronic hepatitis delta virussource ↗
Past FDA Catalysts and PDUFA Decisions
How MIRM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-12 | LIVMARLI (maralixibat) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 12%
Small Cap(rank 80 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Livmarli |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Brelovitug Small moleculeNCT06907290 | Chronic Hepatitis D Infection | Phase 3 | ACTIVE NOT_RECRUITING | 402 | Sep 1, 2029 | ||||||
| Brelovitug Small moleculeNCT07454837 | Chronic Hepatitis D | Phase 2 | RECRUITING | 120 | Mar 30, 2029 | ||||||
| Volixibat Small moleculeNCT04663308 | Primary Sclerosing Cholangitis | Phase 2 | ACTIVE NOT_RECRUITING | 182 | Mar 1, 2028 | ||||||
| Volixibat Small moleculeNCT05050136 | Primary Biliary Cholangitis | Phase 2 | ACTIVE NOT_RECRUITING | 333 | Dec 1, 2028 | ||||||
| Maralixibat Small moleculeNCT06553768 | Cholestatic Liver Disease | Phase 3 | ACTIVE NOT_RECRUITING | 142 | Feb 1, 2027 | ||||||
| Maralixibat Small moleculeNCT07823127 | Intrahepatic Cholestasis of Pregnancy | Phase 2 | NOT YET_RECRUITING | 15 | Jan 12, 2029 | ||||||
| MRM-3379 Small moleculeNCT07209462 | Fragile X Syndrome | Phase 2 | RECRUITING | 60 | Oct 1, 2027 | ||||||
| Blinded CDCA Small moleculeCompletedNCT04270682 | CTX | Phase 3 | COMPLETED | 19 | Oct 4, 2023 | ||||||
| Maralixibat Small moleculeMarketedNCT04729751 | Progressive Familial Intrahepatic Cholestasis | Phase 3 | COMPLETED | 204 | Dec 17, 2024 | ||||||
| Maralixibat Small moleculeMarketedNCT04524390 | Biliary Atresia | Phase 2 | COMPLETED | 75 | Feb 7, 2024 | ||||||
| Cholic acid Small moleculeMarketedNCT01115582 | Inborn Errors of Bile Acid Synthesis | Phase 3 | COMPLETED | 16 | Aug 1, 2010 | ||||||
| Cholic acid Small moleculeMarketedNCT01438411 | Bile Acid Synthesis Defect | Phase 3 | COMPLETED | 53 | Jul 1, 2016 | ||||||
| LUM001 Small moleculeMarketedNCT02057718 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 2 | COMPLETED | 33 | May 8, 2020 | ||||||
| LUM001 Small moleculeMarketedNCT02160782 | Alagille Syndrome | Phase 2 | COMPLETED | 141 | May 28, 2020 | ||||||
| LUM001 Small moleculeMarketedNCT01904058 | PBC | Phase 2 | COMPLETED | 66 | Apr 1, 2015 | ||||||
| LUM001 Small moleculeMarketedNCT02061540 | Primary Sclerosing Cholangitis (PSC) | Phase 2 | COMPLETED | 27 | Feb 1, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every MIRM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATEBRIOZ™ (zilurgisertib) PriorityRare Pediatric | Fibrodysplasia Ossificans Progressiva | 2026-10-26 | favorable clinical responseRead More | Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans ProgressivaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Howe JolandaOfficer (SVP, GLOBAL CONTROLLER) | Option | 16,112 16,728 held | $19.24 | 10/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MIRM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 19.6 % (7.1 %) | 899.06 M | 7.68 M |
MIRM Institutional Ownership Trends
MIRM Short Interest
Shares sold short, counted twice a month.
12.39%
Short % of Float
of tradable shares sold short
6.7M
Shares Sold Short
-4.6% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
912.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MIRM ranks across every disease it competes in
Competitive Position is a premium feature
See how MIRM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMIRM News
MIRM▲ +0.7%today
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
Mirum Pharmaceuticals will announce its third quarter 2026 financial results on November 3, 2026. The company will host a conference call to discuss these results and recent corporate progress. Mirum focuses on rare diseases and has a robust pipeline of investigational medicines.
Read more →MIRM▲ +0.7%today
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ in pediatric patients aged 6 to under 12 with Fibrodysplasia Ossificans Progressiva. The data demonstrated a favorable clinical response in this rare disease population. These findings support the ongoing evaluation of zilurgisertib for treating this condition.
Read more →MIRMMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals announced its participation in several upcoming investor conferences, including Wolfe Research and Stifel Healthcare Conferences in November 2026. The company will host fireside chats and presentations that will be webcast live. Mirum specializes in rare diseases and has a robust pipeline of investigational medicines.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals announced the granting of inducement awards to 18 new employees, including its newly appointed Chief Medical Officer, Rob Myers, M.D. The awards consist of non-qualified stock options and restricted stock units, designed to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). This move reflects Mirum's commitment to expanding its team and enhancing its capabilities in the rare disease market.
Read more →MIRMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals has announced that the primary endpoint has been met in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for treating ultra-rare cholestatic liver diseases. This achievement indicates significant progress in the development of this treatment, which could benefit patients suffering from these conditions.
Read more →MIRMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals has announced an upcoming investor call to discuss the topline results from the Phase 3 EXPAND study of LIVMARLI® (maralixibat). This study targets ultra-rare cholestatic liver diseases, highlighting the company's commitment to addressing significant medical needs. The call aims to provide insights into the findings and implications for future treatments.
Read more →MIRMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals announced that the primary endpoint was met in its Phase 3 AZURE-1 study of Brelovitug for Chronic Hepatitis Delta Virus. This achievement indicates the potential effectiveness of Brelovitug in treating this challenging condition. The results may lead to improved treatment options for patients suffering from this virus.
Read more →MIRMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals announced an upcoming investor call scheduled for September 28, 2026, to discuss the topline results from the Phase 3 AZURE-1 study of Brelovitug in patients with chronic hepatitis delta virus (HDV). This study represents a critical advancement in the treatment options available for this condition.
Read more →MIRMMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have received U.S. FDA approval for Atebrioz™ (zilurgisertib), a treatment for both adult and pediatric patients suffering from Fibrodysplasia Ossificans Progressiva (FOP). This approval marks a significant advancement in addressing the needs of patients with this rare condition. The collaboration highlights the commitment of both companies to develop innovative therapies.
Read more →MIRMMirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Mirum Pharmaceuticals has appointed Dr. Rob Myers as its new Chief Medical Officer. This strategic move is expected to leverage Dr. Myers' extensive experience in the biopharma industry. The appointment reflects the company's commitment to advancing its medical initiatives and improving its leadership team.
Read more →MIRM▼ -11%on this news
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals has released its financial results for the second quarter of 2026, along with a business update. The report highlights key financial metrics and strategic initiatives. Further details on the company's performance and future plans were also shared.
Read more →MIRMMirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Mirum Pharmaceuticals has scheduled a conference call to announce its financial results for the second quarter of 2026. The call will take place on August 5, 2026. This event is part of the company's regular financial reporting.
Read more →MIRMMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have announced positive results from the pivotal Phase 2 PROGRESS study of Zilurgisertib, a treatment for Fibrodysplasia Ossificans Progressiva (FOP). The study's findings indicate potential benefits for patients suffering from this rare condition. This development could pave the way for further advancements in treatment options.
Read more →MIRM▼ -5.1%on this news
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals presented new data at the EASL International Liver Congress 2026, showcasing promising results from its rare liver disease programs. The Phase 2b VISTAS study indicated that volixibat significantly reduces pruritus in primary sclerosing cholangitis (PSC). Additionally, the AZURE-1 study demonstrated the efficacy and safety of brelovitug for chronic hepatitis delta virus (HDV). LIVMARLI also showed improved event-free survival in patients with progressive familial intrahepatic cholestasis (PFIC).
Read more →MIRMMirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals has announced the pricing of a $600 million offering of convertible senior notes due in 2032. The company plans to use the proceeds for general corporate purposes, including the acquisition of complementary products and technologies. Additionally, Mirum will exchange a portion of the proceeds to refinance existing convertible notes due in 2029.
Read more →About Mirum Pharmaceuticals, Inc.
Headquarters989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
BIOPHARMAWATCH ELITE PLUS
Trade the next MIRM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime